Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Livmoniplimab · ABBV-151, ARGX-115

Monoclonal antibody · Antagonist of GARP (LRRC32) · developed by AbbVie

Phase 2/3 Most advanced trial

ABBV Developer

1 Registered trials

What is Livmoniplimab?

Livmoniplimab is a humanized monoclonal antibody that binds GARP (LRRC32), a TGF-beta activator on regulatory T cells. By blocking GARP, it prevents TGF-beta release and reverses immunosuppression, enhancing immune responses against tumor cells. It is being studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ABBV-151, ARGX-115
Drug type: Monoclonal antibody
Targets: GARP (LRRC32), TGF-beta (TGFB1) (secondary target)
Mechanism: Antagonist of GARP (LRRC32)
Pathways: TGF-beta signaling, immune suppression reversal
Therapy area: Oncology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 42SH7JCD82

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06109272	Phase 2/3	Hepatocellular Carcinoma	Active not recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Livmoniplimab

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z